Indication
Idiopathic inflammatory myopathy
2 clinical trials
2 products
2 drugs
Product
CAB-201Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory MyopathyStatus: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic SclerosisStatus: Recruiting, Estimated PCD: 2027-11-15
Product
CC-97540Drug
fludarabineDrug
cyclophosphamide